Pacira BioSciencesFRA:82P +2.75%75 Buyback Yield % is 19.53 as of Jul. 08, 2026, which is 116% above its 10-year median of 9.04. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review. Among 291 Drug Manufacturers companies, Pacira BioSciences ranks better than 98.63% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Pacira BioSciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a Buyback Yield % of 19.53 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pacira BioSciences and its competitors. This is 116% above median its historical median of 9.04. Over the past decade, Pacira BioSciences' Buyback Yield % has ranged from 2.87 to 22.33. According to the industry distribution chart, Pacira BioSciences ranks #4 out of 291 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Pacira BioSciences' Buyback Yield % too high?
Pacira BioSciences' current Buyback Yield % of 19.53 is 116% above median its 10-year median of 9.04. Over the past 10 years, this metric has ranged from a low of 2.87 to a high of 22.33. Based on the distribution chart, Pacira BioSciences ranks #4 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Buyback Yield % compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #4 out of 291 companies for Buyback Yield %. This places Pacira BioSciences in the top 1% of its industry — outperforming the majority of peers. Historically, Pacira BioSciences' own Buyback Yield % has ranged from 2.87 to 22.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Buyback Yield % is 19.53, which is 116% above median its own 10-year median of 9.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Buyback Yield % of 19.53. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Buyback Yield % is 19.53, which is 116% above median its 10-year median of 9.04. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Buyback Yield % is 19.53 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.
Key valuation signals for FRA:82P:
Buyback Yield %: 19.53 (116% above median its 10-year median of 9.04)
GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for FRA:82P
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
